Expression profile and function of Wnt signaling mechanisms in malignant mesothelioma cells

Biochemical and Biophysical Research Communications

Volumn 440, Issue 1, 2013, Pages 82-87

  Fox, Simon A ^a   Richards, Alex K ^a   Kusumah, Ivonne ^a   Perumal, Vanathi ^a   Bolitho, Erin M ^b   Mutsaers, Steven E ^b,c   Dharmarajan, Arun M ^a  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Gene expression; Mesothelioma; Proliferation; Wnt

Indexed keywords

APC PROTEIN; ASBESTOS; AXIN; BETA CATENIN; CISPLATIN; GEMCITABINE; PROTEIN; PROTEIN FZD2; PROTEIN FZD4; PROTEIN FZD6; SECRETED FRIZZLED RELATED PROTEIN 4; UNCLASSIFIED DRUG; WNT PROTEIN; WNT3 PROTEIN; WNT3A PROTEIN; WNT4 PROTEIN; WNT5A PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WNT SIGNALING PATHWAY;

GENE EXPRESSION; MESOTHELIOMA; PROLIFERATION; WNT;

BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESOTHELIOMA; PLEURA; PLEURAL NEOPLASMS; PROTO-ONCOGENE PROTEINS; WNT PROTEINS; WNT SIGNALING PATHWAY; WNT3 PROTEIN;

EID: 84885379222     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.09.025     Document Type: Article

References (41)

1. Spugnini E.P., Bosari S., Citro G., Lorenzon I., Cognetti F., Baldi A. Human malignant mesothelioma: molecular mechanisms of pathogenesis and progression. Int. J. Biochem. Cell Biol. 2006, 38:2000-2004.
2. Ray M., Kindler H.L. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009, 136:888-896.
3. Clevers H., Nusse R. Wnt/β-catenin signaling and disease. Cell 2012, 149:1192-1205.
4. Ilyas M. Wnt signalling and the mechanistic basis of tumour development. J. Pathol. 2005, 205:130-144.
5. Logan C.Y., Nusse R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 2004, 20:781-810.
6. Shigemitsu K., Sekido Y., Usami N., Mori S., Sato M., Horio Y., et al. Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene 2001, 20:4249-4257.
7. Abutaily A.S., Collins J.E., Roche W.R. Cadherins, catenins and APC in pleural malignant mesothelioma. J. Pathol. 2003, 201:355-362.
8. Uematsu K., Kanazawa S., You L., He B., Xu Z., Li K., et al. Wnt pathway activation in mesothelioma: evidence of dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res. 2003, 63:4547-4551.
9. Dai Y., Bedrossian C.W.M., Michael C.W. The expression pattern of beta-catenin in mesothelial proliferative lesions and its diagnostic utilities. Diagn. Cytopathol. 2005, 33:320-324.
10. He B., You L., Uematsu K., Xu Z., Lee A.Y., Matsangou M., et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia New York N. 2004, 6:7-14.
11. Mazieres J., You L., He B., Xu Z., Twogood S., Lee A.Y., et al. Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int. J. Cancer J. Int. Cancer 2005, 117:326-332.
12. Lee A.Y., He B., You L., Dadfarmay S., Xu Z., Mazieres J., et al. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 2004, 23:6672-6676.
13. Kohno H., Amatya V.J., Takeshima Y., Kushitani K., Hattori N., Kohno N., et al. Aberrant promoter methylation of WIF-1 and SFRP1, 2, 4 genes in mesothelioma. Oncol. Rep. 2010, 24:423-431.
14. He B., Lee A.Y., Dadfarmay S., You L., Xu Z., Reguart N., et al. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res. 2005, 65:743-748.
15. You L., He B., Uematsu K., Xu Z., Mazieres J., Lee A., et al. Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res. 2004, 64:3474-3478.
16. Orecchia S., Schillaci F., Salvio M., Libener R., Betta P.-G. Aberrant E-cadherin and gamma-catenin expression in malignant mesothelioma and its diagnostic and biological relevance. Lung Cancer Amst. Neth. 2004, 45(Suppl. 1):S37-43.
17. Fox S., Dharmarajan A. WNT signaling in malignant mesothelioma. Front. Biosci. J. Virtual Libr. 2006, 11:2106-2112.
18. Manning L.S., Whitaker D., Murch A.R., Garlepp M.J., Davis M.R., Musk A.W., et al. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int. J. Cancer J. Int. Cancer. 1991, 47:285-290.
19. Lansley S.M., Searles R.G., Hoi A., Thomas C., Moneta H., Herrick S.E., et al. Mesothelial cell differentiation into osteoblast- and adipocyte-like cells. J. Cell. Mol. Med. 2011, 15:2095-2105.
20. Untergasser A., Cutcutache I., Koressaar T., Ye J., Faircloth B.C., Remm M., et al. Primer3-new capabilities and interfaces. Nucleic Acids Res. 2012, 40:e115.
21. Fox S.A., Loh S.S., Mahendran S.K., Garlepp M.J. Regulated chemokine gene expression in mouse mesothelioma and mesothelial cells: TNF-α upregulates both CC and CXC chemokine genes. Oncol. Rep. 2012, 28:707-713.
22. Whittell L.R., Batty K.T., Wong R.P.M., Bolitho E.M., Fox S.A., Davis T.M.E., et al. Synthesis and antimalarial evaluation of novel isocryptolepine derivatives. Bioorg. Med. Chem. 2011, 19:7519-7525.
23. Erdfelder F., Hertweck M., Filipovich A., Uhrmacher S., Kreuzer K.-A. High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia. Hematol. Reports 2010, 2:e3.
24. Li Y., Wang L., Zhang M., Melamed J., Liu X., Reiter R., et al. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res. 2009, 69:3332-3338.
25. Lin A.Y., Chua M.-S., Choi Y.-L., Yeh W., Kim Y.H., Azzi R., et al. Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker. PloS One 2011, 6:e16636.
26. Nguyen A., Rosner A., Milovanovic T., Hope C., Planutis K., Saha B., et al. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression. Int. J. Oncol. 2005, 27:949-956.
27. Aoki M., Hecht A., Kruse U., Kemler R., Vogt P.K. Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. Proc. Natl. Acad. Sci. USA 1999, 96:139-144.
28. Petropoulos K., Arseni N., Schessl C., Stadler C.R., Rawat V.P.S., Deshpande A.J., et al. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J. Exp. Med. 2008, 205:515-522.
29. Lyons J.P., Mueller U.W., Ji H., Everett C., Fang X., Hsieh J.-C., et al. Wnt-4 activates the canonical beta-catenin-mediated Wnt pathway and binds Frizzled-6 CRD: functional implications of Wnt/beta-catenin activity in kidney epithelial cells. Exp. Cell Res. 2004, 298:369-387.
30. Louis I., Heinonen K.M., Chagraoui J., Vainio S., Sauvageau G., Perreault C. The signaling protein Wnt4 enhances thymopoiesis and expands multipotent hematopoietic progenitors through beta-catenin-independent signaling. Immunity 2008, 29:57-67.
31. Bernard P., Harley V.R. Wnt4 action in gonadal development and sex determination. Int. J. Biochem. Cell Biol. 2007, 39:31-43.
32. Boyer A., Lapointe E., Zheng X., Cowan R.G., Li H., Quirk S.M., et al. WNT4 is required for normal ovarian follicle development and female fertility. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2010, 24:3010-3025.
33. Osada M., Park H.L., Nagakawa Y., Begum S., Yamashita K., Wu G., et al. A novel response element confers p63- and p73-specific activation of the WNT4 promoter. Biochem. Biophys. Res. Commun. 2006, 339:1120-1128.
34. Tanaka S., Terada K., Nohno T. Canonical Wnt signaling is involved in switching from cell proliferation to myogenic differentiation of mouse myoblast cells. J. Mol. Signal. 2011, 6:12.
35. De Menna M., D'Amato V., Ferraro A., Fusco A., Di Lauro R., Garbi C., et al. Wnt4 inhibits cell motility induced by oncogenic Ras. Oncogene 2013, 32:4110-4119.
36. Leung J.Y., Kolligs F.T., Wu R., Zhai Y., Kuick R., Hanash S., et al. Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J. Biol. Chem. 2002, 277:21657-21665.
37. Koinuma K., Yamashita Y., Liu W., Hatanaka H., Kurashina K., Wada T., et al. Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability. Oncogene 2006, 25:139-146.
38. Csepregi A., Röcken C., Hoffmann J., Gu P., Saliger S., Müller O., et al. APC promoter methylation and protein expression in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2008, 134:579-589.
39. Tseng R.-C., Lin R.-K., Wen C.-K., Tseng C., Hsu H.-S., Hsu W.-H., et al. Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis. Oncogene 2008, 27:4488-4496.
40. Olsen A.K., Coskun M., Bzorek M., Kristensen M.H., Danielsen E.T., Jørgensen S., et al. Regulation of APC and AXIN2 expression by intestinal tumor suppressor CDX2 in colon cancer cells. Carcinogenesis 2013, 34:1361-1369.
41. Kawano Y., Kypta R. Secreted antagonists of the Wnt signaling pathway. J. Cell Sci. 2003, 116:2627-2634.